Navigation Links
Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404

Rebecca Skye Dietrich Buchanan Communications +44 (0)20 7466 5000

Brian Korb/Seth Lewis The Trout Group +1 646 378 2900

Antisoma disclaimer Certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Details of the second lung cancer study This trial was conducted as an open-label extension to the first, randomised study of AS1404 in lung cancer. As in the randomised study, patients were receiving first-line chemotherapy treatment for stage IIIb or IV non-small cell lung cancer. All patients received 1800 mg/m2 AS1404 in combination with carboplatin and paclitaxel. The trial was conducted at hospitals in Germany and New Zealand.

Background on AS1404 AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. CRUK had supported two phase I studies in the UK and New Zealand.

Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acqui
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Data supporting three Antisoma programmes presented at AACR
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
8. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma plc Second lung cancer trial adds positive data
(Date:9/15/2014)... Sept. 15, 2014 GenomeDx Biosciences today ... the American Society for Radiation Oncology (ASTRO) Annual ... Cancer Classifier, a genomic test capable of predicting ... and improve patient outcomes for prostate cancer patients ... a recently published study that demonstrates how Decipher ...
(Date:9/15/2014)...  Alere Inc. (NYSE: ALR ) (the ... toxicology, cardiology and diabetes products and services, today confirmed ... CEO Ron Zwanziger , filed a Schedule 13D ... a letter to Gregg J. Powers , Chairman ... in an effort to secure financing to make a ...
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. ... pharmaceutical company with a focus on Omega-3 therapies ... that the Board of Directors approved the granting ... advisor at the close of business on Friday, September ... 1,000,000 common shares of the Company were granted ...
Breaking Medicine Technology:Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Alere Responds To Letter From Former Executives 2Pivotal Therapeutics Grants Incentive Stock Options 2
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... York, NY (PRWEB) September 15, 2014 ... Ariana Grande concert tickets for her 2015 Honeymoon Tour. ... The 21-year-old native of Boca Raton, Florida has been active ... released her first album, which reached the top of the ... the Recording Industry Association of America for selling more than ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 DISCcert, a ... next two-day DISC Certification Workshop for Oct ... will meet locally to take part in the intensive ... effective tools and activities that can be immediately implemented ... to teach trainers to educate employees and staff in ...
(Date:9/15/2014)... Innovative Technology Fund (GHIT Fund), a new public ... investment to the global fight against infectious diseases, ... to speed the development of promising drugs and ... Chagas disease. The announcement marks the GHIT Fund,s ... $33.5 millionaimed at diseases that sicken and kill ...
(Date:9/15/2014)... Today, Zane Benefits, the #1 Online Health Benefits ... radio show. , According to Zane Benefits, health ... doesn’t make sense to choose a “one size fits ... and employee as much as 60 percent on health ... Speaking on Business , Chris Redgrave, highlights the rising ...
(Date:9/15/2014)... 15, 2014 The new North Valley ... 15 near Raintree Dr. and Loop 101, after a ... and dignitaries from the healthcare community on Friday, September ... operating rooms, four gastro-intestinal procedure rooms, and a pain ... the largest surgery center in the state of Arizona. ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 4Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 5Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 2Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 3Health News:New North Valley Surgery Center Is Arizona’s Largest Outpatient Facility 4
... for parents could go a long way toward improving ... a Wayne State University researcher believes. Deborah Ellis, ... of Medicine, has received a two-year, $418,000 grant from ... Diseases of the National Institutes of Health to develop ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
... News) -- A cardiac rehabilitation program appeared to reduce ... among patients who have suffered mild strokes or the ... found. "Overall, following the cardiac rehab intervention, the ... risk profile," study senior investigator Neville Suskin, medical director ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) -- Fred ... evolution of the public health response to human papillomavirus, or ... HPV News , a bimonthly newsletter published by the ... the 1990s. HPV is a sexually transmitted disease that ...
... Sweden: Women diagnosed with breast cancer late in life ... than younger patients, assuming they survive other age-related conditions, ... 2011 European Multidisciplinary Cancer Congress on Saturday. The results ... as well as differences in the progress of the ...
... Gardner HealthDay Reporter , THURSDAY, Sept. 22 ... the credibility of claims that a virus likely causes ... nine different labs around the United States failed to ... the basis of whether they tested positive for xenotropic ...
Cached Medicine News:Health News:Wayne State University study aims to improve diabetes management in high-risk youth 2Health News:Wayne State University study aims to improve diabetes management in high-risk youth 3Health News:Depression After Cancer Keeps Some From Follow-Up Care 2Health News:Cardiac Rehab May Cut Risk Factors After Mini-Stroke 2Health News:Stress the 'Human' in HPV, One Man Suggests 2Health News:Stress the 'Human' in HPV, One Man Suggests 3Health News:Elderly breast cancer patients risk treatment discrimination 2Health News:Elderly breast cancer patients risk treatment discrimination 3Health News:Elderly breast cancer patients risk treatment discrimination 4Health News:New Report Casts More Doubt on Virus' Link to Chronic Fatigue Syndrome 2Health News:New Report Casts More Doubt on Virus' Link to Chronic Fatigue Syndrome 3
Paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
These retractors are packaged singly ready for sterilization at your facility....
These retractors are packaged singly ready for sterilization at your facility....
Medicine Products: